The Lancet Oncology
Fecha de publicación: 13 de abril de 2021
Autores: Claire Petit, MD, Benjamin Lacas, PhD, Jean-Pierre Pignon, MD, Quynh Thu Le, MD, Prof Vincent Grégoire, MD, Prof Cai Grau, MD, Prof Allan Hackshaw, MSc, Björn Zackrisson, MD, Prof Mahesh K B Parmar, DPhil, Ju-Whei Lee, PhD, Maria Grazia Ghi, MD, Giuseppe Sanguineti, MD, Stéphane Temam, MD, Maurice Cheugoua-Zanetsie, MSc, Prof Brian O’Sullivan, MD, Marshall R Posner, MD, Everett E Vokes, MD, et al.
Background: Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other.Leer más